Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anti-urease IgY is a polyclonal antibody derived from the egg yolks of hens immunized with the urease enzyme of *Helicobacter pylori*. Developed by the Immunology Research Institute in Gifu, this passive immunization agent is designed to target and neutralize the urease enzyme, which is critical for *H. pylori* survival in the acidic environment of the stomach. By inhibiting urease, the antibody interferes with bacterial colonization and pathogenicity, potentially offering a therapeutic or preventive approach for gastritis, gastric ulcers, and gastric cancer. It is typically administered orally and acts locally within the gastrointestinal tract to reduce bacterial load and associated inflammation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anti-urease IgY.